Drug Profile
Research programme: small molecule therapeutics - Elorac
Alternative Names: Small molecules Heprotect™Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Gideon Pharmaceuticals
- Developer Elorac
- Class
- Mechanism of Action 14-alpha demethylase inhibitors; Cyclo-oxygenase 2 inhibitors; Retinoic acid receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation; Mycoses; Pain; Psoriasis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route) (Elorac website - September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route) (Elorac website - September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Mycoses in USA (unspecified route) (Elorac website - September 2023)